Moneycontrol PRO

Gland Pharma: Track this inorganic play for the near term

While in the near term, the equity market looks fragile, Gland Pharma makes a cut for the longer haul. This is because of the rising prevalence of chronic diseases and growth of biologics, wherein injectables have a role in treatment and drug delivery

June 24, 2022 / 12:33 PM IST
Gland Pharma: Track this inorganic play for the near term

PRO Only Highlights
Quarterly performance largely backed by improved realisations
Medium-term triggers China plus and protectionist measures for tyre industry
Valuations not inexpensive; but improved medium-term outlook

Gland Pharma (CMP: Rs 2,573; M Cap: Rs 42,375 crore) is a unique play on the expanding domain of generic injectables. So far, its strong CDMO platform and  impeccable regulatory compliance history has helped it to gain a leading market share in some of the generic injectables, such as Levetiracetam, Ondansetron and Vancomycin. However, as competitive intensity increases, one needs to track how the company forays into complex injectables. Supplementing capabilities In FY22, the company has added four production lines at the...

  • PRO Panorama

    Moneycontrol Pro Panorama | ​Can somebody call the bottom already?

    Jun 27, 2022 / 06:35 PM IST

    In today’s edition of Moneycontrol Pro Panorama: The bounce in markets, Fintech trouble, Zomato-Blinkit, IT's defensive traits and more

    Read Now
  • PRO Weekender

    MC Pro Weekender | A new narrative

    Jun 25, 2022 / 12:28 PM IST

    Stock markets are celebrating the turn in inflation, but the bond markets are looking at the coming slowdown

    Read Now

To read the full story, Subscribe to Moneycontrol PRO

Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

Already a member? Sign in

Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

50% OFF

What Do You Get

  • Ad free experience

    Experience a non-intrusive navigation and faster response in the ad free mode

  • Sharpest Opinions

    Access to 230+ exclusive stories per month from our editorial and Experts

  • +

    Have a Global edge with access to content from world renowned experts and journalist

  • Actionable Insights

    Access to 40+ weekly investment ideas including 4 daily technical calls

  • Virtual Events

    Exclusive access to live webinars from market experts on trading and investment strategies

  • Newsletters

    Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

Get upto 50% discount on limited period offers